AAV9-Mediated Gene Replacement Therapy for CTNNB1-Related Neurodevelopmental Disorder

For many families, the path to understanding a child's developmental challenges is long and often frustrating. They may see delays in speech, movement, or learning, but without a clear genetic cause, the condition remains a mystery, and the treatment options are limited to managing symptoms rather than addressing the root problem. One such condition, known as CTNNB1 Syndrome, is caused by a specific error in a single gene. This gene provides the instructions for making a protein called beta-catenin. Think of this protein as a master regulator, a crucial switch that helps build the brain during development and keeps nerve cells communicating properly throughout life. When a person has only one working copy of this gene instead of the usual two, the body does not produce enough of this vital protein. The result is a severe neurodevelopmental disorder characterized by intellectual disability, difficulty with movement, and often features of autism. Until now, there has been no way to fix this missing piece of the puzzle.

A team of researchers, working closely with a patient-led foundation, has taken the first major step toward changing that reality. They have developed and tested a new type of treatment designed to deliver a working copy of the missing gene directly into the brain. Their work, detailed in a recent study, moves from the laboratory bench to living animals, showing that it is possible to restore the missing protein and improve the symptoms of the disease without causing harm. This research represents a critical bridge between the idea of a cure and the actual medical trial that could help patients.

The scientists began by designing a delivery vehicle. They chose a virus that has been modified to be harmless, known as an adeno-associated virus, specifically a type called AAV9. This virus is excellent at entering brain cells and staying there for a long time without causing disease. However, simply putting the gene inside the virus was not enough. The researchers had to engineer the genetic instructions carefully to ensure the right amount of protein was made in the brain, but not in other parts of the body where it could cause trouble. They created six different versions of the treatment package and tested them in tiny, three-dimensional clusters of brain cells grown from the skin cells of patients with the syndrome. These clusters, called organoids, act as a miniature model of the human brain.

After testing these six versions, the researchers found one that worked best. This lead candidate successfully restored the levels of beta-catenin in the patient-derived brain cells to a healthy range. Crucially, when they looked at the activity of the cells after treatment, they saw that the complex networks of genes that control brain development and connection were beginning to function normally again. They also checked to make sure that increasing this protein did not accidentally trigger uncontrolled cell growth, a potential risk with some gene therapies, and found no evidence of such danger. This successful test in the brain models gave them the confidence to move forward.

Next, the team tested the treatment in mice that had been genetically engineered to mimic the human condition. These mice lacked one copy of the beta-catenin gene and showed symptoms similar to the patients, including poor coordination and signs of anxiety. The researchers injected the treatment directly into the fluid-filled spaces of the brain in young mice. They observed the animals over several months, watching how they moved and behaved. The results were clear: the mice that received the highest dose of the treatment showed significant improvements. They became more active, explored their environment more freely, and moved with a steadier, more coordinated gait. Their walking patterns, which had been shaky and unbalanced, began to resemble those of healthy mice. The treatment did not just make them move; it seemed to correct the underlying motor deficits that define the disorder.

Safety is always the most important question when introducing a new therapy into the body. The researchers conducted extensive safety studies to ensure the treatment would not cause unexpected harm. They treated healthy mice and monkeys with the same high doses used in the effective experiments and watched them closely for months. They checked their blood, examined their organs, and looked for any signs of toxicity. The results were reassuring. The animals did not show any signs of liver or kidney damage, which are common concerns with gene therapies. They did not develop tumors, and their behavior remained normal. Even in the monkeys, which have a brain structure much closer to humans, the treatment was well-tolerated. The virus stayed mostly in the brain and spinal cord, as intended, and did not cause inflammation or damage to the nerves in the back or the liver.

The researchers also tracked where the genetic material went inside the body. They found that the treatment reached the brain and the spinal cord effectively, and the genetic instructions remained active there for at least six months. In the rest of the body, the levels of the new protein were very low, which is exactly what they wanted to avoid off-target effects. This careful distribution suggests that the treatment can do its job in the brain without disturbing the rest of the body.

This body of work has paved the way for the next stage of human testing. The safety and effectiveness data gathered from these studies have supported the approval of a clinical trial in Europe, which began in late 2025. This trial will be the first time this specific gene therapy is tested in people with CTNNB1 Syndrome. While the path from a laboratory discovery to a widely available medicine is long and complex, this research provides a solid foundation. It demonstrates that it is possible to correct the genetic error at the heart of this disorder and that doing so can lead to real improvements in how the brain functions. For the families waiting for a treatment that addresses the cause rather than just the symptoms, these findings offer a tangible and hopeful step forward.